Biohaven Pharmaceutical Hold
13F holders, Q4 2024 (December 31)2holders −1
0new positions
1sold out
$37.35avg. 13F price*
At the end of Q4 2024, 2 institutions reported holding Biohaven Pharmaceutical Hold in their 13F filings, down 1 from Q3 2024. 0 opened new positions and 1 sold out. The largest holders were Knoll Capital Management, LLC ($28.4M) and Birchview Capital, LP ($275K).
- Company
- Biohaven Pharmaceutical Hold
- CUSIP
- G11196105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $326K |
All 13F filers, Q3 2024 → Q4 2024: 50,000 shares bought and 6,523 shares sold, net +43,477 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Knoll Capital Management, LLC | 18.28% | Add +7.0% | 760,422 | $28.4M |
| Birchview Capital, LP | 0.22% | No change | 7,365 | $275K |
"% of holder's portfolio" is BIOHAVEN PHARMACEUTICAL HOLD's weight in each manager's 13F, not the share of Biohaven Pharmaceutical Hold the manager owns.